🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Turkey / NCT07656558
Starting soon Not applicable

ACT-Based Psychoeducation for Caregivers of Patients With Schizophrenia

NCT07656558 · tracked via the Priya Life Science Turkey tracker
Phase
Not applicable
Started
2026-07-01
Last updated
2026-06-18

Condition(s) studied

SCHIZOPHRENIA 1 (Disorder)

Investigational drug(s) / intervention(s)

Acceptance and Commitment Therapy (ACT)-Based Psychoeducation Program

Acceptance and Commitment Therapy (ACT)-Based Psychoeducation Program: The intervention consists of an Acceptance and Commitment Therapy (ACT)-based psychoeducation program developed in accordance with expert opinions. The program is delivered in a group format and includes eight structured sessions lasting approximately 60-90 minutes each. Session topics include introduction to the program and ACT principles, contact with the present moment, acceptance, cognitive defusion, self-as-context (observing self), values, values-based actions, and review and evaluation of the psychoeducation process. The intervention is designed to reduce expressed emotion and perceived family burden and to improve psychological flexibility among caregivers of patients with schizophrenia attending a Community Mental Health Center.

Study summary

This randomized controlled trial aims to examine the effects of an Acceptance and Commitment Therapy (ACT)-based psychoeducation program on expressed emotion, perceived family burden, and psychological flexibility among caregivers of patients with schizophrenia attending a Community Mental Health Center.

The main questions this study aims to answer are:

* Does ACT-based psychoeducation reduce expressed emotion among caregivers of patients with schizophrenia?
* Does ACT-based psychoeducation reduce perceived family burden among caregivers of patients with schizophrenia?
* Does ACT-based psychoeducation improve psychological flexibility among caregivers of patients with schizophrenia?

Researchers will randomly assign eligible caregivers to either an intervention group receiving an 8-session ACT-based psychoeducation program or a control group receiving routine care.

Participants will:

* Complete assessment measures before the intervention (pre-test).
* Participate in 8 ACT-based psychoeducation sessions if assigned to the intervention group.
* Continue receiving routine care if assigned to the control group.
* Complete assessment measures immediately after the intervention (post-test).
* Complete follow-up assessments at 1 month and 3 months after the intervention.

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Living with an individual diagnosed with schizophrenia who has been followed and actively receiving services from a Community Mental Health Center for at least one year. * Being the primary caregiver responsible for the care of the individual diagnosed with schizophrenia. * Having been involved in the care and treatment of the individual diagnosed with schizophrenia for at least 12 months prior to the study. * Being between 18 and 65 years of age. * Being literate. * Being able to speak and understand Turkish. * Willing to participate in the study and providing informed consent. Exclusion Criteria: * Having a medically diagnosed psychiatric disorder. * Having a diagnosis of an organic mental disorder or intellectual disability. * Having a physical impairment that may interfere with participation in the study or data collection process (e.g., hearing or speech impairment).

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Nevşehir State Hospital Community Mental Health Center Nevşehir Merkez

More Aydin Adnan Menderes University trials in Turkey

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07656558 on ClinicalTrials.gov ↗ ← All trials in Turkey